COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Impact of Ascorbic Acid in the Prevention of Vancomycin Induced Nephrotoxicty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03921099
Recruitment Status : Recruiting
First Posted : April 19, 2019
Last Update Posted : January 10, 2020
Information provided by (Responsible Party):
Nouran Hesham Ali, Ain Shams University

Brief Summary:
A Randomized controlled trial aiming to investigate whether ascorbic acid has a role in preventing vancomycin induced nephrotoxicity or not in critically ill patients.

Condition or disease Intervention/treatment Phase
Acute Kidney Injury Drug: Ascorbic Acid Phase 4

Detailed Description:
Critically ill patients who have gram positive infection (MRSA) and need vancomycin will be assigned randomly into two groups. The first group will be given vancomycin intravenous only (15-20 mg/kg) every 8-12 hours , while the second group will take vancomycin intravenous (15-20 mg/kg) every 8-12 hours plus ascorbic acid 1 gram twice daily orally just before the vancomycin administration by half an hour. Patients will be monitored for one week where serum creatinine, BUN, urine output, trough level will be measured. Acute kidney injury will be determined according to RIFLE criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Evaluation of the Impact of Ascorbic Acid in the Prevention of Vancomycin Induced Nephrotoxicity
Actual Study Start Date : January 17, 2019
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin C

Arm Intervention/treatment
No Intervention: Vancomycin only
Vancomycin 15-20mg/kg intravenous every 8-12 hours.
Experimental: Vancomycin +Ascorbic acid
Vancomycin 15-20mg/kg intravenous every 8-12 hours. Ascorbic acid 1gm every 12 hours orally just before vancomycin by half an hour for seven days.
Drug: Ascorbic Acid
ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
Other Name: Vitamin C

Primary Outcome Measures :
  1. Incidence of nephrotoxicty [ Time Frame: one week ]
    Incidence of nephrotoxicty will be described according to RIFLE criteria

Secondary Outcome Measures :
  1. 28 days Mortality [ Time Frame: one month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults who are critically ill and with MRSA infection suspection.

Exclusion Criteria:

  1. Pregnancy or breast feeding.
  2. Known allergy to either vancomycin or ascorbic acid.
  3. Base line serum creatinine ≥2mg/dl.
  4. Patients receiving other nephrotoxic drug (e.g., aminoglycosides, amphotericin B, cisplatin or calcinurine inhibitors).
  5. Anticepated administration of contrast medium within 7 days.
  6. Patients suffering from some underlying diseases (e.g., cancer, HIV infection, systemic lupus erythematoses,or urinary tract stones).
  7. Unlikelyhood of receiving the study medications for at least 72 hours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03921099

Layout table for location contacts
Contact: Nouran H Elsherazy, Bachelor +201224959630
Contact: Naglaa S Bazan, PhD

Layout table for location information
Cairo university hospitals Recruiting
Cairo, Egypt, 11562
Contact: Critical care department Cairo university Hopsitals         
Sponsors and Collaborators
Ain Shams University
Layout table for investigator information
Study Director: Nagwa A Sabry, PhD Ain Shams University
Study Director: Sara M Shaheen, PhD Ain Shams University
Layout table for additonal information
Responsible Party: Nouran Hesham Ali, clinical pharmacist at the critical care medicine unit- Cairo university hospitals, Ain Shams University Identifier: NCT03921099    
Other Study ID Numbers: 208
First Posted: April 19, 2019    Key Record Dates
Last Update Posted: January 10, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Ascorbic Acid
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents